Back to search
FDAFDA · Food and drugs·Recall number D-0175-2023

Asthmanefrin Racepinephrine Inhalation Solution Bronchodilator (racephedrine, USP 11.25), 30x0.5 mL Sterile Vials each in a foil pouch, NDC 0487-2784-01 UPC 3 04872 78401 4

Published February 1, 2023 · Recall initiated: January 13, 2023

Summary

FDA records drug Class II recall D-0175-2023, published February 1, 2023 and initiated January 13, 2023. Recalling firm: Nephron Sc Inc; Status: Terminated; Reported quantity: 387,000 vials; Lot: Lot #: 126451 Exp. 04/30/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Short Fill

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Nephron Sc Inc
Distributor
Nationwide within the United States including Puerto Rico. Guatamala
Lot
Lot #: 126451 Exp. 04/30/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Asthmanefrin Racepinephrine Inhalation Solution Bronchodilator (racephedrine, USP 11.25), 30x0.5 mL Sterile Vials each in a foil pouch, NDC 0487-2784-01 UPC 3 04872 78401 4 recalled?

Yes. FDA published recall D-0175-2023 on February 1, 2023. Reported hazard: Short Fill

What should I do if I have this product?

Voluntary: Firm initiated · Letter